EyePoint Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 69 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of EyePoint Pharmaceuticals Inc is 5.98, ranking 144 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 696.00K, representing a year-over-year decrease of 97.15%, while its net profit experienced a year-over-year decrease of 87.70%.
Key Metrics
The current valuation score of EyePoint Pharmaceuticals Inc is 6.10, ranking 131 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -3.52, which is -76.38% below the recent high of -0.83 and -363.40% above the recent low of -16.33.
The current earnings forecast score of EyePoint Pharmaceuticals Inc is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 33.00, with a high of 50.00 and a low of 20.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of EyePoint Pharmaceuticals Inc is 6.23, ranking 122 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 14.34 and the support level at 11.34, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of EyePoint Pharmaceuticals Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 105.59%, representing a quarter-over-quarter decrease of 16.25%. The largest institutional shareholder is Invesco, holding a total of 82.70K shares, representing 0.10% of shares outstanding, with 131.46% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of EyePoint Pharmaceuticals Inc is 4.82, ranking 81 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
